ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2512

Impact of Inflammatory Bowel Disease in Early Spondyloarthritis in a Prospective Longitudinal Cohort

Daniel Wendling1, Xavier Guillot2, Clément Prati3, Rik Lories4 and Maxime Dougados5, 1Service de Rhumatologie, CHU Jean Minjoz, Besancon, France, 2EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France, 4Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 5Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: inflammatory bowel disease (IBD) and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Inflammatory bowel disease (IBD) is a classical extra articular feature of spondyloarthritis (SpA), with increasing evidence of a pathophysiological relationship.

The aims of this study were to evaluate in the DESIR cohort (1) The prevalence of IBD at baseline, and factors (epidemiological, clinical, imaging, biological data available in the database) associated with IBD, (2) The occurrence of new cases of IBD during the M0-M60 follow-up, and factors associated.

Methods:

DESIR is a prospective observational cohort of patients with recent onset (less than 3 years) inflammatory back pain, beginning before 50 years, suggestive of axial SpA, with a planned follow up of ten years. At baseline : identification of patients with IBD (with medical confirmation), analysis of factors (clinical, biological, imaging, treatment) associated with IBD : comparison of patients with and without IBD, for categorical variables : odds-ratio +/- 95% CI and chi-square/Fisher tests, for continuous variables : unpaired t-tests / Mann-Whitney, in uni and then multivariate analysis (logistic regression). Occurrence of new cases of IBD over the five first years of follow-up (database locked on june 20th 2016), and factors associated with IBD at M60 were assessed using uni- and multivariate analysis by logistic regression. Significance : p less than 0.05.

Results:

At baseline, 706 patients were analyzed, 35 had a past history or a concomitant IBD : prevalence 4.94% [CI 95% : 3.3 – 6.5]. IBD was significantly associated (univariate) with ESSG criteria (OR = infinite [2.8-infinite], familial history of IBD (OR = 3.56 [1.01-110.22]) and negatively associated with psoriasis (OR = 0.09 [0.02-0.24]), HLA-B27 (OR = 0.47 [0.21-0.98]) and NSAID score (mean 30.25 (IBD) versus 45.49; p = 0.005). In multivariate analysis IBD was associated positively with familial history of IBD (OR = 5.69 [3.57-7.82]) and negatively with psoriasis (OR = 0.04 [0.035-0.048]) and HLA-B27 (OR = 0.28 [0.26-0.31]). IBD was not associated with phenotypic presentation (peripheral arthritis, enthesitis, dactylitis, uveitis) or baseline serum levels of cytokines (TNF, IL-6, IL-17 A, IL-17 F, IL-23, IL-23). At M60, 617 patients were analyzed, 58 with IBD : prevalence 9.4 %. 23 incident cases of IBD were recorded, giving an estimated occurrence rate of 0.7/100 patient-years in this population. In univariate analysis on prevalent cases, IBD was associated with lower NSAID score (mean 17 versus 19.9, p = 0.029) and a less frequent NSAID response (OR = 0.30 0.13-0.76]), worse activity and function indexes (ASDAS-CRP mean 2.28 versus 2.02; p = 0.038, BASFI mean 29 versus 22; p = 0.019, SF-36 mean 39 versus 44; p = 0.004, HAQ mean 0.75 versus 0.5; p = 0.004, ASQoL mean 8.7 versus 6.6; p = 0.012), and with more family history of IBD (OR = 6.6 [1-40]), more sick leave (mean 21 versus 11 days; p = 0.029), and fulfillment of ESSG criteria. In multivariate analysis, IBD was associated with fulfillment of modified New York criteria (p = 0.04).

Conclusion:

IBD occurs with a rate of 0.7/100 patient-years over 5 years in DESIR cohort, with a negative association at baseline with psoriasis and HLA-B27. At five years, IBD is associated with more severe disease and classification criteria.


Disclosure: D. Wendling, None; X. Guillot, None; C. Prati, None; R. Lories, None; M. Dougados, Abbvie, Pfizer, Lilly, Merck, Novartis, 5,Abbvie, Pfizer, Lilly, Merck, Novartis, 2.

To cite this abstract in AMA style:

Wendling D, Guillot X, Prati C, Lories R, Dougados M. Impact of Inflammatory Bowel Disease in Early Spondyloarthritis in a Prospective Longitudinal Cohort [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/impact-of-inflammatory-bowel-disease-in-early-spondyloarthritis-in-a-prospective-longitudinal-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-inflammatory-bowel-disease-in-early-spondyloarthritis-in-a-prospective-longitudinal-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology